Combined Administration of Oxycodone/Naloxone in Chronic Osteo-Articular Diseases Pain Therapy by Palomba, Rosa et al.
Translational Medicine @ UniSa, - ISSN 2239-9747 2013, 9(8) 38-42 
 
38 
Università degli Studi di Salerno 
COMBINED ADMINISTRATION OF OXYCODONE/NALOXONE IN 














Department  of Anesthesia, Rianimation, Intensive Therapy and  Pain Therapy 
 University “Federico II” Naples, Italy. 
 
Corresponding author: Palomba Rosa - e-mail: giovannini47@libero.it 
 
 
Abstract - The aim of this study is the analysis of the 
beneficial impact of using opioid receptor antagonist 
associated to opioid analgesic on the quality of life in 
patients suffering from chronic non-cancer pain.  
We recruited 60 patients suffering from osteo-
articular diseases who were randomized into two groups 
of treatment. The group A was treated with the 
association of opioid receptor antagonist and opioid 
agonist, represented by Oxycodone. The group B was 
treated with the opioid analgesics Oxycodone, 
transdermal Fentanil, and Hidromorphone, without the 
opioid antagonist. The end-points assessed were the 
duration of titration, the average reached dosage, the 
duration of the stability of dosage and the opioid–induced 
constipation (OIC) using the BFI. 
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Several studies demonstrated the analgesic efficacy of 
using long-term opioids for chronic non-cancer pain. In 
these years, in fact, the opioid treatment of benign 
diseases, such as osteo-articular diseases, burdened with 
moderate to severe chronic pain, increased. Use of opioid 
analgesics, with or without paracetamol, is useful 
especially in patients in whom NSAIDs are 
contraindicated, ineffective, and/or poorly tolerated [1].  
The analgesic effect of opioids is mediated by the 
binding to specific receptors in the central nervous 
system. The binding of opioids to receptors in the gastro-
intestinal tract, instead, is responsible for the main side 
effects reported by patients such as abdominal distension, 
incomplete evacuation, gastro-oesophageal reflux and 
especially opioid-induced constipation (OIC). The opioid-
induced constipation unlike other effects, does not 
undergo tolerance and therefore it has a significant effect 
on the patient’s quality of life. The treatment of OIC with 
laxatives is nonspecific and often unsuccessful.  
Recently, it has been demonstrated that the 
prevalence of constipation reached 63.5% in patients 
treated with opioids. Since 89,5% of these patients does 
not take advantage of laxatives administration, the author 
suggests that the best strategy is prevention [2].  
The prevention of the OIC can be obtained by 
administrating opioid receptor antagonists that act at the 
GI level, without interfering with analgesia. These 
objectives can be achieved with the use of naloxone, 
which has low bioavailability after oral administration, 
equivalent to 3%, acting almost exclusively on GI 
receptors. Naloxone is commercially available as a single 
entity, in intravenous (IV) dosage form, which is 
indicated for the blockade of exogenously administered 
opioids. In the oral dosage form, Naloxone is available 
only in the combined formulation with the Oxycodone, in 
the ratio of 1:2 [3]. Thanks to this association, the drug is 
able to produce the analgesic effect determined by the 
action of oxycodone on µ- and κ-receptors, and of 
naloxone as antagonist of the opioids receptors only at GI 
level. This prevents and fights the onset of opioid-induced 
constipation without reducing the analgesic effect of 
oxycodone [4].  
Wang and collaborators demonstrated that the use of 
Naloxone in low doses can alleviate opioid tolerance, 
with mechanisms not yet completely defined, that 
probably reside in the switch of the μ-receptor G-protein-
associated or in activating adenylate cyclase. This 
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additional effect would influence the effective dose of the 
agonist opioid and the time within this dose is steady [5].  
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Our research was authorized by Ethic Committee of 
University Federico II. In this study we recruited 60 
patients (age 59-73) suffering from chronic osteo-articular 
diseases in stable condition, with pain assessment using 
visual analogic scale (VAS) of 7 or more; we excluded 
patients with serious organ failure, history of alcoholism 
or drug addiction, cognitive impairment. All the patients 
where asked to consent to the use of personal data. The 
patients were randomized into two treatment groups: the 
Group A (31 patients) took the combination 
oxycodone/naloxone with paracetamol in cyclic 
administration; the Group B (29 patients) took other 
opioid analgesics (6 pz fentanyl transdermal, 13 pz 
hydromorphone, 10 pz oxycodone) with paracetamol in 
cyclic administration. The effects of the combination of 
opioid antagonist and agonist were evaluated in terms of: 
 
• Duration of the titration; 
• Average reached dosage, expressed in a relation 
with an equivalent dosage of morphine; 
• Duration of the stability of dosage; 
• Incidence of OIC through the administration of the 
BFI, a questionnaire relating to bowel function 
estimated on the basis of 3 items: difficulties in 
the evacuation (0-100; 0 = no difficulty, 100 = 
severe difficulty), sensation of incomplete 
evacuation (0-100, 0 = absent, 100 = very strong), 
personal evaluation of constipation (0-100, 0 = 
none, 100 = very stubborn). The BFI was 
evaluated at enrollment in the study (T1), at 1 
month (T2), and at the end of follow-up (T3). 
The results obtained in the two different groups were 





Fixed endpoints were evaluated for both treatment 
groups. 
Titration had an average duration of 14.97 days ± 
6.01 in Group A and 17.07 days ± 5.11 in Group B (fig. 
1).  
The reached average dosage was compared by 
converting the dosage of the opioid in the equivalent 
dosage of morphine, through the use of equianalgesia 
tables. This comparison shows that in Group A the mean 
dose achieved, expressed as mg of morphine, is equal to 
72 ± 13.22, while in Group B the mean dose achieved is 
80 (fig.2).  
The shelf life of an effective dose was found to be 
77.03 days ± 8.02 for Group A and 58.38 days ± 4.55 for 
group B (fig.3).. The patients of Group B needed a drug 
increase in a shorter time to control the pain. 
The opioid-induced constipation, estimated by 
administration of the BFI, was assessed at enrollment in 
the study (T1), at 1 month (T2), and at the end of follow-
up (T3). At enrollment (T1) the values of BFI were on 
average of 46.35 ± 3.14 for the Group A and 66.17 ± 6.41 
for the Group B. At 1 month (T2) BFI was increased just 
to 50.84 ± 4.14 for the group A, while it raised up to 
77.22 ± 4.58 for the Group B. At the term of follow-up 
(T3) BFI decreased to 46.42 ± 5.40 in the Group A, while 
it increased, although barely, to 79.59 ± 5.09 in the Group 





The results of the study show that a therapy based on 
the association of an opioid receptor antagonist, such as 
naloxone, with opioid analgesics, provides a number of 
advantages. These benefits are reflected in a positive way 




Fig. 1: Duration of Titration 
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Fig. 3: Shelf-life of an effective dose                                                                 
                
 
 
                                                                 
Fig. 4: BFI during the follow-up 
 
The use of naloxone in the group A is associated with 
a lower temporal extension of the titration, towards a 
dosage with analgesic efficacy and an average dosage 
expressed in terms of analgesic equivalence with 
morphine; this analgesic efficacy is lower than that 
recorded in group B, treated with opioid analgesics 
without the antagonist. Analgesic efficacy was considered 
good when the score was <6 in the visual analog scale of 
pain relief. Moreover, the dosage is stable for a greater 
time range. This results in better adherence to therapy and 
increased patient satisfaction, key elements in the 
treatment of chronic benign diseases. These results can be 
attributed to the role of the antagonist in the inhibition of 
opioid tolerance, already shown by experimental studies 
on animals [6] [7].  
According to data, already available in the literature, 
Naloxone has proven useful in breaking the opioid-
induced constipation, with a clear improvement of bowel 
function without any interference with the analgesic 





The results obtained from the study show that the 
combination oxycodone-naloxone allows for greater 
stability in the maintenance of dosing, once you find a 
suitable dose for each patient, as well as it increased 
quality of life, as indicated by the best BFI index values 
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